Update on the transfusion in gastrointestinal bleeding (TRIGGER) trial: statistical analysis plan for a cluster-randomised feasibility trial by Kahan, BC et al.
Update on the transfusion in gastrointestinal bleeding (TRIGGER) trial:
statistical analysis plan for a cluster-randomised feasibility trial.
Kahan, BC; Jairath, V; Murphy, MF; Doré, CJ
 
 
 
 
 
© Kahan et al.; licensee BioMed Central Ltd. 2013
CC-BY
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/12262
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
UPDATE Open Access
Update on the transfusion in gastrointestinal
bleeding (TRIGGER) trial: statistical analysis plan
for a cluster-randomised feasibility trial
Brennan C Kahan1*, Vipul Jairath2,3, Michael F Murphy2,4,5 and Caroline J Doré1
Abstract
Background: Previous research has suggested an association between more liberal red blood cell (RBC) transfusion
and greater risk of further bleeding and mortality following acute upper gastrointestinal bleeding (AUGIB).
Methods and design: The Transfusion in Gastrointestinal Bleeding (TRIGGER) trial is a pragmatic cluster-randomised
feasibility trial which aims to evaluate the feasibility of implementing a restrictive vs. liberal RBC transfusion policy
for adult patients admitted to hospital with AUGIB in the UK. This trial will help to inform the design and
methodology of a phase III trial. The protocol for TRIGGER has been published in Transfusion Medicine Reviews.
Recruitment began in September 2012 and was completed in March 2013. This update presents the statistical
analysis plan, detailing how analysis of the TRIGGER trial will be performed. It is hoped that prospective publication
of the full statistical analysis plan will increase transparency and give readers a clear overview of how TRIGGER will
be analysed.
Trial registration: ISRCTN85757829
Keywords: Statistical analysis plan, Cluster randomised trial, Transfusion, Gastrointestinal bleeding, Variceal bleeding,
Feasibility trial
Update
Introduction
Acute Upper Gastrointestinal Bleeding (AUGIB) is the
most common reason for emergency hospital admission
with a gastrointestinal disorder in the United Kingdom
(UK) with an annual incidence of 50 to 150/100,000
adults [1]. It is also the leading indication for red blood
cell (RBC) transfusion, accounting for 14% of all RBCs
transfused in England [2]. RBC transfusion is commonly
based upon the patient’s haemoglobin (Hb) level; how-
ever, the optimal Hb threshold at which to transfuse is
unclear [3,4]. Two observational studies have indicated
an association between RBC transfusion after AUGIB
and risk of further bleeding and mortality [5,6]. A recently
published randomised trial found a liberal approach to
transfusion led to an increased risk of mortality [7], al-
though these results may not be generalisable due to the
strict protocols of care implemented in this single centre
trial, which are unlikely to be reproducible in most
healthcare institutions.
The Transfusion in Gastrointestinal Bleeding (TRIGGER)
trial is a cluster-randomised trial designed to evaluate
the feasibility of implementing a restrictive vs. liberal
RBC transfusion policy for patients admitted to hospital
with AUGIB [8]. TRIGGER is a pragmatic trial which
aims to reflect real world settings as closely as possible.
Six hospitals in the United Kingdom were randomised
in a 1:1 ratio to follow either a liberal transfusion pol-
icy (where eligible patients are transfused when their
Hb drops below 10 g/dL) or a restrictive transfusion pol-
icy (where eligible patients are transfused when their Hb
drops below 8 g/dL). Randomisation was performed
using permuted blocks without stratification or matching,
with a block size of six (to ensure three hospitals in
each arm). Hospitals were randomised in July 2012, and
recruitment took place between September 2012 and
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The TRIGGER protocol has been published in Transfu-
sion Medicine Reviews [8] (available at www.tmreviews.
com), and gives details on the rationale for the study, the
inclusion/exclusion criteria, the sample size calculation
and the process for consenting patients to the trial. This
update to the published protocol describes the statistical
analysis plan for TRIGGER.
The TRIGGER trial was conducted according to
the declaration of Helsinki, and received ethical ap-
proval from the Scotland A Research Ethics Committee
(Reference 12/SS/0023) and the NRES Committee South
Central – Oxford C (Reference 12/SC/0062).
Outcomes
This trial will report both feasibility and clinical out-
comes. Outcome definitions and explanations are avail-
able in the protocol [8].
Feasibility outcomes
The feasibility outcomes are:
 The proportion of eligible patients who provide
consent
 The proportion of screened patients who are
ineligible due to need for immediate transfusion
 Overall protocol adherence
 Protocol adherence per patient
 Protocol adherence per Hb count
 Baseline characteristics of consented patients (age,
shock, Hb, clinical Rockall score [9], Blatchford score
[10] (two commonly used risk scores), and number of
major co-morbidities for consented patients)
 The difference between consented vs non-consented
patients for baseline Hb, Rockall and Blatchford scores
 The number of RBC units transfused
 The proportion of patients receiving at least one
RBC transfusion
 Mean Hb over the first seven days, up to discharge,
and over the entire study period
 Differences between consented patients and those
discharged before being approached for consent in
the Rockall and Blatchford scores, and baseline Hb.
The intra-class correlation coefficient and its 95%
confidence interval from this feasibility trial will also
be presented.
Clinical outcomes
The clinical outcomes are:
 Further bleeding up to Day 28 (primary clinical
outcome)
 Further bleeding up to hospital discharge
 All-cause mortality up to Day 28
 All-cause mortality up to hospital discharge
 Therapeutic intervention at the index endoscopy
 Surgical or radiological intervention to control
bleeding up to death or discharge
 Occurrence of a thromboembolic or ischaemic event
up to Day 28
 Occurrence of a thromboembolic or ischaemic event
up to hospital discharge
 Acute transfusion reactions up to death or discharge
 Infection up to Day 28
 Infection up to hospital discharge
 Length of hospital stay
 Health related quality of life at Day 28
 Serious adverse events (SAEs) up to Day 28
The individual components that make up the composite
outcome of a thromboembolic or ischaemic event (myo-
cardial infarction, stroke, pulmonary embolus, deep vein
thrombosis, and acute kidney injury) will also be analysed
separately at both Day 28 and at hospital discharge.
Analysis principles
Feasibility outcomes
Analysis of the feasibility outcomes will be by intention-
to-treat (ITT), and will include all consented patients on
whom an outcome is available, unless otherwise stated.
A secondary analysis will include all consented patients
with a recorded Hb below 12 g/dL during follow-up, and
for whom an outcome is available (this secondary ana-
lysis will be restricted to RBC transfusion outcomes, Hb
concentration outcomes, and adherence outcomes). A
5% significance level will be used. All analyses of feasibil-
ity outcomes will be unadjusted for baseline covariates.
Clinical outcomes
Main analysis of the clinical outcomes will be by ITT,
and will include all consented patients with a recorded
Hb below 12 g/dL during follow-up, and for whom
the outcome is available. Including only patients with
a Hb <12 g/dL allows us to target those patients most
likely to be affected by the treatment policy, resulting
in a more powerful analysis on a more relevant patient
population. A Hb of 12 g/dL was chosen as the cut-off
point because it is likely that some patients will be
transfused (against policy) above 10 g/dL; if the propor-
tion of patients transfused above 10 g/dL differs between
treatment arms, excluding these patients could lead to
bias. Using a cut-off of 12 g/dL should allow the majority
of transfused patients to be included in the analysis, lead-
ing to an unbiased comparison. A secondary analysis will
include all consented patients, regardless of whether their
Hb dropped below 12 g/dL.
Results will be considered statistically significant at the
5% level. Main analyses for clinical outcomes will be
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unadjusted for baseline covariates; however, a set of
secondary analyses will be adjusted for patient age, the
presence of shock, the number of major co-morbidities,
and the presence of coagulopathy (defined as an inter-
national normalised ratio (INR) >1.5 or a prothrombin
time (PT) >3 seconds greater than the control). Mean im-
putation within the centre will be used for patients with
missing baseline covariates [11]. Patient age and the num-
ber of major co-morbidities (encompassing ischaemic heart
disease, cardiac failure, liver disease, renal disease, respira-
tory disease, malignancy and stroke) will be modelled using
fractional polynomials to allow for the possibility of a non-
linear association [12]. Further bleeding up to Day 28 is
regarded as the primary clinical outcome.
Analysis methods
All analyses will account for clustering to ensure correct
type I error rates and confidence intervals [13-15]. Many
cluster randomised trials base their analysis on individual
level patient data, and use appropriate statistical methods
to account for clustering between patients in the same
cluster (for example, mixed-effects models or generalised
estimating equations). However, analysis methods based
on individual level patient data may not perform well
when the number of clusters is small [13,14]. Analysis for
TRIGGER will, therefore, be performed using cluster-
level summaries, which performs well even with a very
small number of clusters [13,14].
Equal weight will be given to each of the six clusters.
All analyses will compare the two treatment arms, unless
otherwise stated. Binary outcomes will be presented as a
difference in proportions.
Unadjusted analyses
Unadjusted analyses using cluster-level summaries can be
performed by calculating a summary outcome from each
centre, and fitting a linear regression model with the sum-
mary outcome as a response variable, and treatment arm as
a covariate. For example, for the outcome of mortality, one
might choose the proportion of patients who died as a
summary measure. To perform the analysis, one would
then need to calculate the proportion of patients who died
in each centre. A linear regression model would then be fit-
ted, with the proportion of patients who died in each centre
as the outcome, and which treatment the centre was
randomised to as a covariate (in the TRIGGER trial there
would only be six data points, as there are only six centres).
Adjusted analyses
Adjusted analyses using cluster-level summaries will be
performed as follows [14]:
1) A regression model (linear for continuous outcomes
and logistic for binary outcomes) will be fit to
individual-level patient data, and will be adjusted for
the baseline characteristics listed earlier (age, shock,
presence of coagulopathy and the number of major
co-morbidities). The model will not adjust for
treatment effect, or for centre.
2) Predicted values based on the fitted regression
model will be calculated for each patient (for binary
outcomes this equates to the predicted probability of
experiencing an event, for continuous outcomes this
equates to the predicted mean).
3) The expected outcome in each cluster will be
calculated. For binary outcomes, this is the
expected number of events in each cluster, and is
calculated by summing the predicted probabilities
for each patient in that cluster. For continuous
outcomes, the expected mean value is calculated
by taking the mean of the predicted values in
each cluster.
4) An appropriate residual is calculated for each
cluster. For binary outcomes, this is the observed
number of events minus the expected number of
events, divided by the number of patients in the
cluster. For continuous outcomes, this is the
observed mean minus the expected mean.
5) A linear regression model will be fit using the
residuals calculated above as cluster-level
summaries, with only the treatment group as a
covariate. No degrees of freedom correction will be
made for performing an adjusted analysis, as only
patient-level variables will be adjusted for.
Cluster level summaries for feasibility outcomes
Cluster-level summaries for feasibility outcomes will be
calculated separately in each centre as follows:
1) Recruitment rate (patients consenting): the
proportion of eligible patients providing consent.
2) Ineligible due to severity of bleeding: the
proportion of screened patients who are ineligible
due to severity of bleeding
3) Overall adherence: the mean adherence rate per
patient
4) Adherence per patient: the proportion of patients
who had no protocol deviations
5) Adherence per Hb count: the proportion of Hb
counts that did not lead to a protocol deviation
6) Selection bias - baseline variables for consented
patients: The mean age, baseline Hb, number of
major co-morbidities, clinical Rockall score and
Blatchford score, and the proportion of patients
with shock will be calculated for consented patients.
7) Selection bias - difference between consented and
non-consented patients in baseline variables: The
difference in the mean Rockall score and Blatchford
Kahan et al. Trials 2013, 14:206 Page 3 of 6
http://www.trialsjournal.com/content/14/1/206
score, and mean baseline Hb between consented
and non-consented patients will be calculated in
each centre.
8) Red blood cell exposure (number of transfusions):
the mean number of RBC units transfused per
patient.
9) Red blood cell exposure (patients receiving at
least one transfusion): the proportion of patients
who receive at least one RBC transfusion.
10)Hb concentration up to Day 7, and over the
entire in-hospital follow-up period, prior to
discharge/death/Day28: the area-under-the-curve
will be calculated for each patient
11) Hb concentration at discharge: the mean Hb
will be calculated
Cluster level summaries for clinical outcomes
The cluster-level summary will be calculated as the pro-
portion of patients in each centre experiencing the event
of interest for the following outcomes: further bleeding,
all-cause mortality, need for therapeutic intervention at
index endoscopy, need for surgery or radiological inter-
vention to control bleeding, any thromboembolic or is-
chaemic events (and each of the components separately),
acute transfusion reactions, infections and SAEs.
A cluster-level summary for length of hospital stay will
be calculated using the median length of stay in each
centre, and a cluster-level summary for health related
quality of life will be calculated using the mean EQ-5D
[16] in each centre.
Subgroup analyses
Subgroup analyses will be performed for two outcomes:
further bleeding and all-cause mortality (both up to
Day 28) using an interaction test, and considered statis-
tically significant at the 5% level. The following sub-
group analyses will be performed:
 Variceal vs. non-variceal bleeding
 Ischaemic heart disease vs. no ischaemic heart disease
Interaction tests will be performed by calculating the
difference in proportions (for the chosen outcome) be-
tween subgroups within each centre [14]. A linear re-
gression model will then be fit, with the difference in
proportions between subgroups as the outcome, and
treatment as a covariate. Interaction tests will be un-
adjusted for baseline covariates, and will be reported
with a 95% confidence interval.
Sensitivity analyses
Missing data for each clinical outcome will be summarised
by treatment arm. Sensitivity to missing data for further
bleeding and all-cause mortality up to Day 28 will be
assessed under a range of missing-not-at-random scenar-
ios. This will be done by calculating the mean outcome in
each cluster as follows:
xobsð Þ

1−pmissing

þ

xsensitivity

pmissing
 
where xobs is the observed cluster level summary, pmissing is
the proportion of patients with missing data in that cluster,
and xsensitivity is the proportion of patients with missing
data who are assumed to have had the event of interest.
xsensitivity will be varied between 0, 0.2, 0.4, 0.6, 0.8 and 1.
The treatment effect and 95% confidence interval will be
calculated as before.
Discussion
It has become increasingly common in recent years to
prospectively publish trial protocols to increase trans-
parency by allowing a comparison between what was
presented in the final manuscript and what was planned
in the protocol before trial results were known [17-20].
The rationale for prospectively publishing trial protocols
also applies to statistical analysis plans.
There are generally a number of different ways to analyse
an outcome in a clinical trial. For example, analyses could
adjust for different covariates, or be completely unadjusted
[21-24]; if covariates were adjusted for in the analysis, this
could be performed in different ways (for example, using
Mantel-Haenszel estimates, or an adjusted logistic regres-
sion model for binary outcomes [25]). In multicentre trials,
one could either ignore the centre-effects, or account for
them in a number of different ways (for example, using
fixed or random effects [26-28]). Issues regarding multipli-
city (for example, when taking multiple looks at the data
through interim analyses, or through multiple pairwise
comparisons between treatment groups) may or may not
be accounted for in the analysis [29].
It is hoped that results will be robust, and will give
similar conclusions regardless of the method of analysis
used. However, different analysis methods will often give
different results, either through chance or because some
analysis methods are more appropriate in certain situa-
tions. It is important for trialists to pre-specify the
method of analysis to prevent them from assessing the
data using several different methods of analysis, and pre-
senting the most favourable result.
The benefits from a prospectively published statistical
analysis plan can be seen from a randomised trial pub-
lished in 2013 [30]. The trial used a group sequential de-
sign, which is known to lead to biased estimates of
treatment effect and inflated type I error rates if it is not
properly accounted for in the trial analysis [29]. In this
trial, accounting for the group sequential nature of the
trial would have given a non-significant result for the
primary outcome, whereas ignoring it gave a statistically
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significant result. The manuscript presented the signifi-
cant result as their primary analysis; had the statistical
analysis plan been prospectively published prior to data
analysis it would have given readers more confidence
that the method of analysis had not been chosen based
on whether or not it gave a statistically significant result.
We are, therefore, prospectively publishing the statis-
tical analysis plan for the TRIGGER trial to increase
transparency, and to provide readers with a more
complete picture of the methods that will be used to ana-
lyse the trial. The statistical analysis plan was signed off
in February 2013, before any trial investigators had access
to the trial database. Recruitment to TRIGGER began in
September 2012 and finished in March 2013.
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